Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia

被引:27
|
作者
Graupner, Oliver [1 ]
Karge, Anne [1 ]
Flechsenhar, Sarah [1 ]
Seiler, Alina [1 ]
Haller, Bernhard [2 ]
Ortiz, Javier U. [1 ]
Lobmaier, Silvia M. [1 ]
Axt-Fliedner, Roland [3 ]
Enzensberger, Christian [3 ]
Abel, Kathrin [1 ]
Kuschel, Bettina [1 ]
机构
[1] Univ Hosp rechts Isar, Syst Univ Munich, Dept Obstet, Gynecology, Ismaninger Str. 22, DE-81675 Munich, Germany
[2] Univ Hosp rechts Isar, Syst Univ Munich,Inst Med Informat,Stat,Epidmiol, IMedIS, Munich, Germany
[3] Univ Hosp UKGM, Liebig Univ,Dept Obstet,Div Prenatal Med, Gynecology,Justus, Giessen, Germany
关键词
Preeclampsia; (anti-) Angiogenic factors; Placental growth factor; Soluble fms-like tyrosine kinase 1; Cerebroplacental ratio; Uterine artery Doppler; FETAL-GROWTH RESTRICTION; UTERINE ARTERY DOPPLER; CEREBROPLACENTAL RATIO; ANGIOGENIC FACTORS; PREGNANCY; WOMEN; RISK; TERM; CLASSIFICATION; DIAGNOSIS;
D O I
10.1007/s00404-019-05365-9
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose The sFlt-1 (soluble fms-like tyrosine kinase-1)/PlGF (placental growth factor) ratio and uterine artery Doppler have shown to be helpful in the diagnosis of pre-eclampsia (PE). The predictive value of the cerebroplacental ratio (CPR) regarding adverse perinatal outcome (APO) in low-risk pregnancies is intensively discussed. We evaluated the extent to which sFlt-1/PlGF ratio and feto-maternal Doppler may be useful in predicting APO in singleton pregnancies complicated by late-onset PE and/or HELLP syndrome. Methods This is a retrospective study from 2010 to 2018 consisting of singleton pregnancies with confirmed diagnosis of late-onset (lo >= 34 weeks) PE/HELLP syndrome in which sFlt-1/PlGF ratio and feto-maternal Doppler (mUtA-PI: mean uterine artery pulsatility index and CPR) were determined. The ability of sFlt-1/PlGF ratio, mUtA-PI, CPR and their combination to predict APO or SGA was evaluated using receiver operating characteristic (ROC) curves. Results 67 patients were included in the final analysis. Of these, sFlt-1/PlGF was > 110 (defining angiogenic lo PE) in 40.3% (27/67), mUtA-PI was above the 95th centile in 34.3% (23/67) patients and CPR was lower than the 5th centile in 10.4% (7/67). Abnormal sFlt-1/PlGF and mUtA-PI as well as CPR were associated with a lower birth weight (BW). Late-preterm birth (< 37 weeks) as well as postnatal diagnosis of small for gestational age (SGA: BW < 3rd centile) was significantly more often in angiogenic lo PE cases. Neither sFlt-1/PIGF nor CPR or mUtA-PI were APO predictors. Only for sFlt-1/PlGF, ROC analysis revealed a significant predictive value for postnatal SGA (AUC = 0.856, p = 0.001, 95% CI 0.75-0.97). There was no statistical added value of combined SGA predictors as compared to sFlt-1/PlGF alone. Conclusions In patients with lo PE, adding sFlt-1/PlGF ratio to routine antepartum fetal surveillance may be useful to identify cases of postnatal SGA. However, further prospective studies are warranted to define the role of feto-maternal Doppler and sFlt-1/PlGF ratio as outcome predictors.
引用
收藏
页码:375 / 385
页数:11
相关论文
共 50 条
  • [21] Role of vitamin D and sFlt-1/PlGF ratio in the development of early- and late-onset preeclampsia
    Alvarez-Fernandez, Indira
    Prieto, Belen
    Rodriguez, Veronica
    Ruano, Yolanda
    Escudero, Ana I.
    Alvarez, Francisco V.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (07) : 1033 - 1040
  • [22] Feto-maternal correlation of PTX3, sFlt-1 and PlGF in physiological and pre-eclamptic pregnancies
    Algeri, Paola
    Ornaghi, Sara
    Bernasconi, Davide Paolo
    Cappellini, Fabrizio
    Signorini, Stefano
    Brambilla, Paolo
    Urban, Gabriele
    Vergani, Patrizia
    HYPERTENSION IN PREGNANCY, 2014, 33 (03) : 360 - 370
  • [23] Evaluation of sFlt-1/PlGF Ratio for Predicting and Improving Clinical Management of Pre-eclampsia: Experience in a Specialized Perinatal Care Center
    Caillon, Helene
    Tardif, Cecile
    Dumontet, Erwan
    Winer, Norbert
    Masson, Damien
    ANNALS OF LABORATORY MEDICINE, 2018, 38 (02) : 95 - 101
  • [24] Low sFlt-1/PlGF- ratio Low short-term Pre-eclampsia Risk
    Lorenz, Judith
    ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2016, 220 (03):
  • [25] Predictive value of sFlt-1, PlGF, sFlt-1/PlGF ratio and PAPP-A for late-onset preeclampsia and IUGR between 32 and 37 weeks of pregnancy
    Birdir, C.
    Droste, L.
    Fox, L.
    Frank, M.
    Fryze, J.
    Enekwe, A.
    Koeninger, A.
    Kimmig, R.
    Schmidt, B.
    Gellhaus, A.
    PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH, 2018, 12 : 124 - 128
  • [26] Effect of magnesium sulfate combined with labetalol on serum sFlt-1/PlGF ratio in patients with early-onset severe pre-eclampsia
    Wang, Ying
    Bao, Jing
    Peng, Min
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 20 (06)
  • [27] Improved Prediction of Adverse Pregnancy Outcome With the sFlt-1/PlGF Ratio in Patients Suspected of Preeclampsia?
    Verdonk, Koen
    van Ingen, Manon
    Smilde, Johanna E.
    Steegers, Eric A.
    Danser, A. H. Jan
    van den Meiracker, Anton H.
    Visser, Willy
    HYPERTENSION, 2013, 62 (03)
  • [28] ECONOMIC EVALUATION OF THE SFLT-1/PLGF RATIO TEST TO GUIDE THE MANAGEMENT OF CHINESE SUSPECTED PRE-ECLAMPSIA WOMEN
    Chen, Y.
    Huang, Z.
    VALUE IN HEALTH, 2019, 22 : S673 - S673
  • [29] Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction
    Stepan, H.
    Galindo, A.
    Hund, M.
    Schlembach, D.
    Sillman, J.
    Surbek, D.
    Vatish, M.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2023, 61 (02) : 168 - 180
  • [30] A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PlGF ratio and NT-proBNP as biomarkers
    Lafuente-Ganuza, Paula
    Lequerica-Fernandez, Paloma
    Carretero, Francisco
    Escudero, Ana, I
    Martinez-Morillo, Eduardo
    Sabria, Enric
    Herraiz, Ignacio
    Galindo, Alberto
    Lopez, Ana
    Martinez-Triguero, Maria L.
    Alvarez, Francisco, V
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2020, 58 (03) : 399 - 407